We are excited to publish the Hepatitis C Market Memo 2022, a brief covering the latest trends in the hepatitis C diagnostics and treatment markets since the publication of CHAI’s second HCV Market Intelligence Report in August 2021. This memo provides updates on key volume and pricing trends and the availability of quality-assured diagnostic and generic direct-acting antiviral (DAA) in the market. It also sheds light on emerging market frontiers like hepatitis C virus (HCV) self-testing and the HCV pediatric market.
We will publish another interim memo on the HBV market later this year, including intel and strategies for hepatitis B virus (HBV) programs and patients to access tenofovir, medication used to treat chronic hepatitis B and to prevent and treat HIV, at the same low price as accessed by HIV programs. A full market report on HCV and HBV will be published in 2023.
Correction Dec 2, 2022: The in-country price for 12 Weeks Treatment Course (USD) of SOF/DCV in India, showcased in the graph on Pg. 2 of the Hepatitis C Market Memo, was wrongly indicated as US$117 instead of US$39. This has been corrected to US$39.
